FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2117064749> ?p ?o ?g. }

• W2117064749 endingPage "376" @default.
• W2117064749 startingPage "371" @default.
• W2117064749 abstract "Weekly dosing of paclitaxel has been demonstrated to be a well-tolerated, feasible and effective administration schedule. In this study, we evaluated the efficacy and safety of weekly paclitaxel in Japanese women with advanced or metastatic breast cancer.Seventy-four patients were enrolled in the study. Paclitaxel was administered by 1 h intravenous infusion at a dose of 80 mg/m2 every week. Administration was continued for 3 weeks followed by a 1 week rest. A short premedication, consisting of dexamethasone 10 mg, ranitidine 50 mg and diphenylhydramine 50 mg, was given prior to each dose of paclitaxel. Eligibility criteria included an Eastern Cooperative Oncology Group performance status of 0, 1 or 2 and adequate hematological, hepatic and renal function.Of 74 patients treated and evaluable for toxicities, 70 were evaluable for response. The mean age was 57.7 years. Forty-nine patients (66.2%) had received prior anthracyclines for metastatic diseases. The overall response rate among 74 patients was 40.5%, including 4.1% complete responses and 36.5% partial responses. The median follow-up time was 481 days (range, 24-903 days). The median time to progression was 4.8 months and median overall survival was 15.8 months. The majority of patients tolerated the treatment very well. Although alopecia was observed in most of the patients (93.2%), grade 3 or 4 neutropenia was 10.8% and grade 2 or 3 peripheral neuropathy was 13.5%.Weekly paclitaxel as a 1 h infusion was active and generally well tolerated in previously treated patients. Further study of weekly paclitaxel in combination therapy is warranted." @default.
• W2117064749 created "2016-06-24" @default.
• W2117064749 creator A5012661910 @default.
• W2117064749 creator A5020511258 @default.
• W2117064749 creator A5040258765 @default.
• W2117064749 creator A5044126941 @default.
• W2117064749 creator A5050071752 @default.
• W2117064749 creator A5064799818 @default.
• W2117064749 creator A5072475537 @default.
• W2117064749 creator A5080331745 @default.
• W2117064749 creator A5082836616 @default.
• W2117064749 date "2003-08-01" @default.
• W2117064749 modified "2023-09-26" @default.
• W2117064749 title "Multicenter Phase II Trial of Weekly Paclitaxel for Advanced or Metastatic Breast Cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01)" @default.
• W2117064749 cites W1888433797 @default.
• W2117064749 cites W1924346446 @default.
• W2117064749 cites W1938913042 @default.
• W2117064749 cites W1940754997 @default.
• W2117064749 cites W1946819517 @default.
• W2117064749 cites W1979300931 @default.
• W2117064749 cites W2059972525 @default.
• W2117064749 cites W2064367468 @default.
• W2117064749 cites W2109815554 @default.
• W2117064749 cites W2114612380 @default.
• W2117064749 cites W2128848742 @default.
• W2117064749 cites W2133243551 @default.
• W2117064749 cites W2148700329 @default.
• W2117064749 cites W2157800681 @default.
• W2117064749 cites W2178225042 @default.
• W2117064749 cites W2227235589 @default.
• W2117064749 cites W2412278054 @default.
• W2117064749 cites W2418488720 @default.
• W2117064749 cites W2982501661 @default.
• W2117064749 cites W3145402682 @default.
• W2117064749 doi "https://doi.org/10.1093/jjco/hyg075" @default.
• W2117064749 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14523055" @default.
• W2117064749 hasPublicationYear "2003" @default.
• W2117064749 type Work @default.
• W2117064749 sameAs 2117064749 @default.
• W2117064749 citedByCount "24" @default.
• W2117064749 countsByYear W21170647492012 @default.
• W2117064749 countsByYear W21170647492015 @default.
• W2117064749 countsByYear W21170647492016 @default.
• W2117064749 countsByYear W21170647492017 @default.
• W2117064749 countsByYear W21170647492019 @default.
• W2117064749 countsByYear W21170647492021 @default.
• W2117064749 countsByYear W21170647492022 @default.
• W2117064749 crossrefType "journal-article" @default.
• W2117064749 hasAuthorship W2117064749A5012661910 @default.
• W2117064749 hasAuthorship W2117064749A5020511258 @default.
• W2117064749 hasAuthorship W2117064749A5040258765 @default.
• W2117064749 hasAuthorship W2117064749A5044126941 @default.
• W2117064749 hasAuthorship W2117064749A5050071752 @default.
• W2117064749 hasAuthorship W2117064749A5064799818 @default.
• W2117064749 hasAuthorship W2117064749A5072475537 @default.
• W2117064749 hasAuthorship W2117064749A5080331745 @default.
• W2117064749 hasAuthorship W2117064749A5082836616 @default.
• W2117064749 hasBestOaLocation W21170647491 @default.
• W2117064749 hasConcept C121608353 @default.
• W2117064749 hasConcept C126322002 @default.
• W2117064749 hasConcept C141071460 @default.
• W2117064749 hasConcept C2775930923 @default.
• W2117064749 hasConcept C2776694085 @default.
• W2117064749 hasConcept C2777063308 @default.
• W2117064749 hasConcept C2777288759 @default.
• W2117064749 hasConcept C2777292972 @default.
• W2117064749 hasConcept C2778300832 @default.
• W2117064749 hasConcept C2778850193 @default.
• W2117064749 hasConcept C530470458 @default.
• W2117064749 hasConcept C71924100 @default.
• W2117064749 hasConcept C90924648 @default.
• W2117064749 hasConceptScore W2117064749C121608353 @default.
• W2117064749 hasConceptScore W2117064749C126322002 @default.
• W2117064749 hasConceptScore W2117064749C141071460 @default.
• W2117064749 hasConceptScore W2117064749C2775930923 @default.
• W2117064749 hasConceptScore W2117064749C2776694085 @default.
• W2117064749 hasConceptScore W2117064749C2777063308 @default.
• W2117064749 hasConceptScore W2117064749C2777288759 @default.
• W2117064749 hasConceptScore W2117064749C2777292972 @default.
• W2117064749 hasConceptScore W2117064749C2778300832 @default.
• W2117064749 hasConceptScore W2117064749C2778850193 @default.
• W2117064749 hasConceptScore W2117064749C530470458 @default.
• W2117064749 hasConceptScore W2117064749C71924100 @default.
• W2117064749 hasConceptScore W2117064749C90924648 @default.
• W2117064749 hasIssue "8" @default.
• W2117064749 hasLocation W21170647491 @default.
• W2117064749 hasLocation W21170647492 @default.
• W2117064749 hasOpenAccess W2117064749 @default.
• W2117064749 hasPrimaryLocation W21170647491 @default.
• W2117064749 hasRelatedWork W1975239262 @default.
• W2117064749 hasRelatedWork W2006416360 @default.
• W2117064749 hasRelatedWork W2024155108 @default.
• W2117064749 hasRelatedWork W2048754569 @default.
• W2117064749 hasRelatedWork W2063667079 @default.
• W2117064749 hasRelatedWork W2117972559 @default.
• W2117064749 hasRelatedWork W2164934025 @default.
• W2117064749 hasRelatedWork W2380876728 @default.
• W2117064749 hasRelatedWork W2418610963 @default.

• next